NCT02149004 German Centre for Infection Research HIV Translational Platform
| NCT ID | NCT02149004 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Cologne |
| Condition | HIV |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2015-04 |
| Primary Completion | 2035-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2015-04 with a primary completion date of 2035-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite major advances in therapy and management, HIV/AIDS continues to be a major cause of infectious disease morbidity and mortality on a global scale. The discovery of effective antiretroviral treatment has turned HIV infection into a manageable chronic disease in most patients with access to care. However, the different economic and epidemiologic situation in developing and developed countries requires different research priorities, so that three main challanges are universal and in focus of research of the DZIF HIV Translational Platform: * Prevention of HIV infection * Long-term life with HIV * HIV cure The "Translation Reserach HIV" will bring together clinical researchers in HIV infection in order to develop new treatment options to the above mentioned main challanges. It will take advantage of existing expertise (e.g. basic science, novel targets for treatment and HIV eradiation) of the partner sites. This platform is necessary because Germany's HIV research has suffered in the past from a lack of integration between its excellent basic science and clinical research. In addition, there was too little integration into networks that address the main international challenges. There is an urgent need to link these research strands through dedicated structures emphasising the translation of preclinical results into new therapies.
Eligibility Criteria
Inclusion Criteria: * HIV positive Exclusion Criteria: * None
Contact & Investigator
Jörg Janne Vehreschild, MD
PRINCIPAL INVESTIGATOR
University Hospital of Cologne
Frequently Asked Questions
Who can join the NCT02149004 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02149004 currently recruiting?
Yes, NCT02149004 is actively recruiting participants. Contact the research team at janne.vehreschild@ctuc.de for enrollment information.
Where is the NCT02149004 trial being conducted?
This trial is being conducted at Cologne, Germany.
Who is sponsoring the NCT02149004 clinical trial?
NCT02149004 is sponsored by University Hospital of Cologne. The principal investigator is Jörg Janne Vehreschild, MD at University Hospital of Cologne. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.